Key facts
- AcuamarkDx’s last known valuation is $85.0M (Jun 2024).
- It has raised $25.0M; the latest was Later Stage VC ($4.9M) in Apr 2026.
- Notable investors include 1955 Capital, Bruker, Cornell University, HBS Alumni Angels of Greater New York, XLerateHealth.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for AcuamarkDx
- ·The full record, as it builds
Funding rounds
No funding rounds for AcuamarkDx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AcuamarkDx
Developer of a cancer screening blood technology designed to detect cancer markers at early stages. The company's technology integrates a suite of novel, multiplexed assays that test for several levels of molecular change through frequent, recurrent, sequential monitoring and screening, enabling doctors to get a scalable and economical blood-based screening result for early detection of cancer, heart disease, thyroid function, and diabetes.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2012
- Employees
- 8
- Website
- acuamarkdx.com/
- Ownership
- Privately Held (backing)
AcuamarkDx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AcuamarkDx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AcuamarkDx in its N-PORT filings yet. We sweep new filings monthly.